• Table of Contents

    Jan 5, 2026, 12:03

  • Toward a Common Ground for Defining Digital Health Interventions, Mapping Digital Health Frameworks to PICOTS-ComTeC: An ISPOR Special Interest Group Report

    Jan 1, 2026, 00:00

  • Unlocking Patient Preferences: The Potential of Stated-Preference Methods in Clinical Decision Making

    Jan 1, 2026, 00:00

  • Clinical Outcomes and Measures for Vaginal Relaxation Syndrome: A Systematic Review

    Jan 1, 2026, 00:00

  • A Head-to-Head Comparison of the Psychometric Properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D in Children Aged 8 to 18 Years With Eczema

    Jan 1, 2026, 00:00

  • Incorporating Informal Caregiving Time Into Cost-Effectiveness Analysis for Adults Aged 50 and Older: Estimating From Health-Related Quality of Life and Functional Status

    Jan 1, 2026, 00:00

  • Application of International Reference Pricing Rules to Forecast Pharmaceutical Launch Prices in 5 European Countries

    Jan 1, 2026, 00:00

  • Operationalizing Distributional Cost-Effectiveness in Genomic Medicine: A United States–Focused Comment

    Jan 1, 2026, 00:00

  • Cost-Effectiveness of the 15 Drugs Selected for Initial Price Applicability Year 2027 by Centers for Medicare and Medicaid Services Drug Price Negotiation Program

    Jan 1, 2026, 00:00

  • Integrating Price Benchmarks and Comparative Clinical Effectiveness to Predict Initial Price Offers for Medicare Drug Price Negotiation (Initial Price Applicability Year 2027)

    Jan 1, 2026, 00:00

  • Pharmaceutical Pricing Evidence From a Healthcare System With Multiple Cost-per-Quality-Adjusted Life-Year Thresholds

    Jan 1, 2026, 00:00

  • Methodological Insights From Health Valuation Studies in Low- and Middle-Income Countries: A Scoping Review

    Jan 1, 2026, 00:00

  • The Cost-Effectiveness of Collagenase Injection Versus Limited Fasciectomy for Moderate Dupuytren’s Contracture: An Economic Evaluation of the Dupuytren’s Interventions Surgery Versus Collagenase Trial and a Decision Analytical Model

    Jan 1, 2026, 00:00

  • Comparing Adolescent and Adult Preferences for EQ-5D-Y-3L Health States in Hong Kong

    Jan 1, 2026, 00:00

  • Adult Social Care Outcomes Toolkit and ICEpop Capability Measure in Decision Making: A Review of NICE Social Care and Public Health Guidelines

    Jan 1, 2026, 00:00

  • Implications of Value Set Choice on EQ-5D-Y-3L Child and Proxy Health-Related Quality of Life Ratings: What to Do When a Country-Specific “Y” Value Set Is Unavailable?

    Jan 1, 2026, 00:00

  • Predicting Healthcare Utilization Outcomes With Artificial Intelligence: A Large Scoping Review

    Jan 1, 2026, 00:00

  • Health Inequality Aversion in the United States

    Jan 1, 2026, 00:00

  • A Generalized Risk-Adjusted Cost-Effectiveness Economic Model for Measuring the Value of Interventions That Delay Mobility Impairment Across Neurological Conditions

    Jan 1, 2026, 00:00

  • Combining Simulation Model-Based Outcomes With County-Level Data for Geographic Health Equity Impact Evaluations of New Interventions

    Jan 1, 2026, 00:00

  • Editorial Board

    Jan 1, 2026, 00:00

  • Disclaimer

    Dec 19, 2025, 11:50

  • Editorial Board

    Dec 16, 2025, 09:49

  • OP1 Bridging the Gap Between AI Principles and Practi A Comparative Evaluation of AI Position Statements and Frameworks for Responsible Use

    Dec 1, 2025, 00:00

  • HSD100 Rising Polypharmacy Trends and Associated Factors in Chinese Adults With Diabetes: A Population-Based Cohort Study

    Dec 1, 2025, 00:00

  • HPR207 The Intercept of Real-World Evidence (RWE) Health Equity and Health Technology Assessment (HTA): A Structured Literature Review of Health Policy and Methodological Guidance

    Dec 1, 2025, 00:00

  • HPR218 Through a Glass Darkly: The What, How, and What Now for Global Net Price Transparency

    Dec 1, 2025, 00:00

  • EE460 Factors Associated With the Highest Costs Among US Adults With Primary Biliary Cholangitis

    Dec 1, 2025, 00:00

  • HSD93 Real-World Differences in Breast Cancer Management by Detection Method: A Czech National Analysis

    Dec 1, 2025, 00:00

  • EE491 Health Economic Evaluation Model for Pancreatic Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)

    Dec 1, 2025, 00:00

  • EPH180 Pharosight: A Shiny-Based Interactive Platform With LLM-Enhanced Analyses and Predictive Modeling for Real-World Prescription Data

    Dec 1, 2025, 00:00

  • CO242 The Impact of Network Meta-Analyses on HTA Decisions in Oncology: A Review of NICE Appraisals

    Dec 1, 2025, 00:00

  • SA12 An Interactive Tool to Select Indirect Treatment Comparison Methods for Rapid Feasibility Assessment

    Dec 1, 2025, 00:00

  • EPH211 Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy Patients in the Brazilian Public Health System: A Real-World Study

    Dec 1, 2025, 00:00

  • HTA291 Rising EAP Rejection Rates and Their Impact on Drug Access in France

    Dec 1, 2025, 00:00

  • EPH52 Cost-Effectiveness Analysis Of The 13-Valent And 20-Valent Pneumococcal Conjugate Vaccine In The Kazakh Adult Population

    Dec 1, 2025, 00:00

  • EE152 Considerations for Modeling Caregiver Spillover Within Economic Evaluations for Neurological Disorders: Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy (DMD), and Multiple Sclerosis (MS)

    Dec 1, 2025, 00:00

  • EE649 Requirements for Payer Recognition of Disease-Modifying Effect in New Drug Launches

    Dec 1, 2025, 00:00

  • PCR85 Evaluation and Validation of the Hypoparathyroidism Daily Diary of Symptom Experience (HPT-DD-SE) and the Hypoparathyroidism Life Impact Questionnaire (HPT-LIQ)

    Dec 1, 2025, 00:00

  • HPR158 Perceived Impact and Actionability of Barriers to Drug Repurposing: Insights From a Multistakeholder Policy Survey

    Dec 1, 2025, 00:00

  • P32 The Healthcare Improvement Scotland Think Frailty Tool: A Preliminary Psychometric Evaluation

    Dec 1, 2025, 00:00

  • HTA139 Evolution of Acceptance of Evidence and PMA Outcomes by HTA Authorities for ATMPs in the EU4 and the UK 2017-2025

    Dec 1, 2025, 00:00

  • EE104 Budget Impact of an Ambulatory Minimally Invasive Surgical Treatment in an Italian Public Hospital

    Dec 1, 2025, 00:00

  • HTA205 Integrating Health Equity Into Health Technology Assessment: A Scoping Review

    Dec 1, 2025, 00:00

  • EPH124 Heatstroke Is Associated With an Increased Risk of Chronic Headache: A Retrospective Cohort Study in Germany

    Dec 1, 2025, 00:00

  • EE571 Management of Moderate-to-Highly Exuding Leg Ulcers with Polyacrylate Dressings vs. Foam Dressings in Spanish Settings: An Early Stage Cost-Effectiveness and Budget-Impact Analysis

    Dec 1, 2025, 00:00

  • MSR45 Bayesian Parametric Mixture Cure Survival Models With Delayed Treatment Effects and Application to Targeted Therapies in Advanced Ovarian Cancer

    Dec 1, 2025, 00:00

  • MT31 National Competent Authorities’ Experiences With Early Feasibility Study Assessment: Promoting Dialogue, Supporting Sponsors, and Fostering Shared Learning to Harmonize the EU Framework

    Dec 1, 2025, 00:00

  • PCR75 Enhancing Understanding of Quality of Life in Multiple Sclerosis Through Social Listening: Complementing Traditional HRQoL Measures

    Dec 1, 2025, 00:00

  • HPR98 Fragmentation in Access Pathways: A Review of HTA and Decision-Making Processes for Medicines in Finland

    Dec 1, 2025, 00:00

  • HPR200 The Evolving Horizon of Oncology: Predicting the Impact of the EU HTA Regulation for 2026-2029

    Dec 1, 2025, 00:00

  • EE738 Treatment With Semaglutide Reduces the Complication Costs Among Type 2 Diabetes Patients With CKD in China: A Short-Term Cost Analysis Based on the FLOW Trial

    Dec 1, 2025, 00:00

  • HTA190 HTA Submission Trends for EMA-Approved Oncology NASs Prior to the EU HTA Regulation 2018-2023

    Dec 1, 2025, 00:00

  • HSD106 The DM77 and Rare Diseases: Analysis of Regional Legislation in Italy

    Dec 1, 2025, 00:00

  • PCR72 Enhancing Equity in Cancer Clinical Trials: A Synthesis of Patient-Reported Barriers and Sustainable Solutions

    Dec 1, 2025, 00:00

  • PCR205 Real-World Drivers of Adherence in Obesity Highlight the Need for Patient-Centered Interventions

    Dec 1, 2025, 00:00

  • PCR162 Multinational Qualitative Testing of the Experimental EuroQol Toddler and Infant Populations (EQ-TIPS) Instrument

    Dec 1, 2025, 00:00

  • HTA341 Treatment Effect Extrapolation Assumptions in NICE Highly Specialized Technology Appraisals

    Dec 1, 2025, 00:00

  • EE213 Cost-Effectiveness Analysis of Oral Semaglutide As a Third-Line Treatment for Patients With Type 2 Diabetes Mellitus

    Dec 1, 2025, 00:00

  • HTA107 Development and Validation of a Machine Learning Model for Predicting French HAS ASMR Ratings Using Product and Disease Characteristics

    Dec 1, 2025, 00:00

  • EPH55 COVID-19 mRNA-1273 Vaccination in the UK: A Comparative Modeling Study of Alternative Eligibility Criteria

    Dec 1, 2025, 00:00

  • SA36 Economic Burden Utilities and Cost-Effectiveness of Perioperative Immunotherapies for Early Stage Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • HTA159 Funding the Fight Against Antimicrobial Resistan Learnings From the UK and Sweden’s Pilot Incentive Programs

    Dec 1, 2025, 00:00

  • EPH168 Mutagenicity of Imazalil, Pyrimethanil, and Thiabendazole With and Without Citrus Oil

    Dec 1, 2025, 00:00

  • HTA307 Surrogate Outcome Validation Within the New EU HTA Guidance Framework: Practical Considerations From an Industry Perspective Based on Experience From HTA Germany

    Dec 1, 2025, 00:00

  • HTA32 Analysis of Pros Included in the HTA Assessment of Conditionally Approved Oncology Drugs in the UK, Italy, and Germany

    Dec 1, 2025, 00:00

  • RWD144 Real-World Healthcare Resource Utilization and Related Costs Associated With Schizophrenia in the Brazilian Private Market

    Dec 1, 2025, 00:00

  • HTA208 Integrating Real-World Evidence for Advanced Therapies in Inflammatory Bowel Disease Into Reimbursement Submissions: Insights and Considerations From the UK

    Dec 1, 2025, 00:00

  • HPR232 Use of High-Cost Medicines in Secondary Care Settings in the English National Health Service

    Dec 1, 2025, 00:00

  • EE204 Cost-Effectiveness Analysis of Image-Guided Ablation vs. Conventional Ablation in Patients With Recurrent Ventricular Tachycardia: Results From the inEurHeart Trial

    Dec 1, 2025, 00:00

  • SA35 Disease-Free Survival as a Surrogate Endpoint for Overall Survival in Patients With Adjuvant Treatments for Completely Resected Stage I-III Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analyses

    Dec 1, 2025, 00:00

  • EE342 Does Modeling Adherence Matter? Insights From Prior NICE Appraisals

    Dec 1, 2025, 00:00

  • HTA151 From French Early Access to Regular Reimbursement: How Do Prices Shift Post-HTA?

    Dec 1, 2025, 00:00

  • EE681 Systems Simulation Methods for the Economic Evaluation of Non-Medicines and Nonsurgical Interventions: A Systematic Literature Review of Quality and Methods for Reproducing Complexity in Health and Health Behaviors

    Dec 1, 2025, 00:00

  • EE477 Forecasting Uptake of Novel Drugs Used for Atopic Dermatitis in Sweden Based on Historic RWE

    Dec 1, 2025, 00:00

  • HPR10 A Strategic National Framework for Managed Entry Agreements to Access Innovative and Breakthrough Medications in Saudi Arabia

    Dec 1, 2025, 00:00

  • EE740 Uncovering the Cost Landscape of Congenital Heart Disease (CHD) With a Life Course Perspective: A Systematic Review of Healthcare Utilization by Lesion Type and Age

    Dec 1, 2025, 00:00

  • MSR161 Overfitting Mitigation in Neural Networks: Could Ergodic Regularization Be the Future of AI?

    Dec 1, 2025, 00:00

  • HPR227 Understanding Reimbursement and Access Policies for Immunoglobulins and Other Plasma-Derived Medicinal Products Across Europe

    Dec 1, 2025, 00:00

  • SA38 Enhancing Targeted Literature Reviews (TLRs) with Artificial Intelligence (AI): A Methodological Approach for Conducting Efficient Targeted Searches

    Dec 1, 2025, 00:00

  • EE400 Economic Impact of Lenalidomide-Refractory Multiple Myeloma in Finland: Insights From Real-World Data

    Dec 1, 2025, 00:00

  • RWD166 Real-World Utilization Pattern of GLP-1 Receptor Agonists in German Outpatient Care

    Dec 1, 2025, 00:00

  • EE90 Budget Impact Analysis of Introducing the Elecsys® PRO-C3 Assay as Part of the ADAPT Algorithm for Assessing the Severity of Hepatic Fibrosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in the UK

    Dec 1, 2025, 00:00

  • EE189 Cost Utility Analysis of a Digital Peer Navigation Program for Men With Prostate Cancer

    Dec 1, 2025, 00:00

  • HTA305 Supplementing Single-Arm Trial Data in NICE Submissions: Are Synthetic Approaches Leading the Charge?

    Dec 1, 2025, 00:00

  • CO233 The Association Between COVID-19 Vaccination and the Healthcare Resource Use Related to COVID-19 in Typical Rural Residents in Japan

    Dec 1, 2025, 00:00

  • EE404 Economic Value of Dupilumab in Preventing and Treating Comorbid Asthma in Pediatric Patients With Atopic Dermatitis: A Cost-Offset Model From the Italian Payer Perspective

    Dec 1, 2025, 00:00

  • CO148 Incidence of Treatment-Related Adverse Events From Immune Checkpoint Inhibitors: A Meta-Analysis of Randomized Clinical Trials

    Dec 1, 2025, 00:00

  • HSD54 Guideline-Driven Off-Label Oncology Use: The Role of Clinical Evidence and Reimbursement Dynamics in the EU4+UK, Switzerland, and Canada

    Dec 1, 2025, 00:00

  • EE264 Cost-Effectiveness of Nivolumab Plus Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable NSCLC in Greece

    Dec 1, 2025, 00:00

  • HPR33 Barriers and Facilitators Influencing the Development of Complex Generics: An Exploratory Study

    Dec 1, 2025, 00:00

  • MSR196 The AI-Only Workflow: Model and Report Adaptation Without Human Setup

    Dec 1, 2025, 00:00

  • CO169 Network Meta-Analysis NMA of Clinical Effectiveness of Second-Line (2L+) Treatments in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    Dec 1, 2025, 00:00

  • RWD31 Characterization of a Large-Scale Real-World Data Sour Impact of Linking Closed Claims With Electronic Health Record Data

    Dec 1, 2025, 00:00

  • HTA299 Simulated Treatment Comparisons in NICE Technology Appraisals: Frequency Trends and Implications

    Dec 1, 2025, 00:00

  • EE553 Informing the Sustainable Development of Novel Therapies Using Value-Based Real Options Analysis

    Dec 1, 2025, 00:00

  • HPR5 A Comparative Analysis of Similarities and Differences of RWE Standards Across Regulatory and Health Technology Assessment Bodies

    Dec 1, 2025, 00:00

  • CO77 Comparative Efficacy of Ongericimab Versus Six PCSK9 Inhibitors in Treating Hypercholesterolemia or Mixed Dyslipidemia: A Network Meta-Analysis

    Dec 1, 2025, 00:00

  • EPH129 Hospitalization and Healthcare Consumption Burden of Respiratory Syncytial Virus (RSV) in Adults Over 50 years in France (RESVYR Study)

    Dec 1, 2025, 00:00

  • EE362 Economic Burden of Pneumococcal Disease—Impact of Age and Underlying Medical Conditions

    Dec 1, 2025, 00:00

  • EE327 Development of a Discrete Event Simulation Model to Explore the Potential Cost-Effectiveness for Cancer Early Detection Testing in Female BRCA Carriers

    Dec 1, 2025, 00:00

  • EE179 Cost of Care for Relapsing/Remitting Multiple Sclerosis Treatments: A Pharmacoeconomic Evaluation From the Spanish Healthcare System Perspective

    Dec 1, 2025, 00:00

  • HTA129 Evaluating an Augmented Reality Software for Mechanical Thrombectomy Using the Lean Assessment Process Methodology: Identifying Clinical Needs, Stakeholder Acceptance, and Adoption Barriers in the NHS

    Dec 1, 2025, 00:00

  • EE707 The Economic Value of Self-Administered Subcutaneous Immunoglobulin G (SCIg) in Canada: A Scoping Review

    Dec 1, 2025, 00:00

  • HPR27 Annual Change in Türkiye’s Reimbursement List: A Comparative Descriptive Analysis of the 2023 and 2024 SUT Annex 4-A Lists

    Dec 1, 2025, 00:00

  • CO3 A Systematic Literature Review and Network Meta-Analysis of Once-Weekly Icosema With Daily Fixed-Dose Combinations of Basal Insulin and GLP-1 RA in Patients With Type 2 Diabetes After 52 Weeks of Treatment

    Dec 1, 2025, 00:00

  • SA102 Viable Rate of Return for Social Impact Bonds Supporting Research and Development of Gene Therapies for Rare Conditions

    Dec 1, 2025, 00:00

  • RWD107 Institutional Trends and Healthcare Resource Utilization in Real-World NMIBC and MIBC Treatment in Germany

    Dec 1, 2025, 00:00

  • EE482 Half-Cycle Correction: It’s Time to Let It Go

    Dec 1, 2025, 00:00

  • HPR153 Orphan Drugs Availability in Israel: A Base for Policy Development

    Dec 1, 2025, 00:00

  • MSR38 Assessing Accuracy of Unsupervised Large Language Model Tools for Identifying Key Criteria Supporting Abstract Screening

    Dec 1, 2025, 00:00

  • HPR210 The New Discount on Combination Drug Therapies in Germany: First Numbers and Assessment From a Payor Perspective

    Dec 1, 2025, 00:00

  • MSR42 Automating PICOs Criteria Assessment in Systematic Reviews With LLMs: Insights From Two Case Studies

    Dec 1, 2025, 00:00

  • EE410 Enhancing Healthcare Cost Communication Through Visualization: A Decision Tree Framework

    Dec 1, 2025, 00:00

  • MSR34 Artificial Intelligence Detection of National Clinical Practice Gaps in Hormone-Sensitive Prostate Cancer (HSPC) in Brazil: A Patient-Centered Framework

    Dec 1, 2025, 00:00

  • CO20 Association Between ALK Tyrosine Kinase Inhibitor and the Risk of Interstitial Lung Disease and Pneumonitis in Non-Small Cell Lung Cancer Patients: A Systematic Review

    Dec 1, 2025, 00:00

  • EE486 Healthcare Resource Utilization and Costs Among Various Disease States in Adults With Hepatitis Delta Virus in Inpatient and Outpatient Settings in the United States

    Dec 1, 2025, 00:00

  • HTA135 Evaluating the Role of Societal Perspectives in the EU Joint Clinical Assessment Framework and in EU-27 Health Technology Assessment Guidelines

    Dec 1, 2025, 00:00

  • EE682 Targeted Literature Review Informing Economic Model Structures in Atherosclerotic Cardiovascular Disease

    Dec 1, 2025, 00:00

  • EPH206 Real-World Uptake of SGLT2i Usage in Patients With Chronic Kidney Disease or Heart Failure: A German Claims Data Analysis

    Dec 1, 2025, 00:00

  • RWD126 MIRROR KEYNOTE: Generating Real-World External Control Arms in Non-Small Cell Lung Cancer Using a Curated Database

    Dec 1, 2025, 00:00

  • PCR138 Increased Adherence to Biologic Therapies Leads to Lower All-Cause and Asthma-Related (HCRU) Costs in Severe Asthma

    Dec 1, 2025, 00:00

  • EPH201 Quantification of the HPV-Attributable Cancer Mortality in Gree Years of Life Lost and Productivity Costs

    Dec 1, 2025, 00:00

  • EE185 Cost per Responder Analysis of Teclistamab Compared to Real-World Physician’s Choice of Carfilzomib and/or Pomalidomide-Based Regimens for Triple-Class Exposed Patients With Refractory/Relapsed Multiple Myeloma

    Dec 1, 2025, 00:00

  • PT4 Developing a Novel Model Structure for Evaluating Treatment Sequences in Oncology Pathways: A Pilot in Non-Small Cell Lung Cancer

    Dec 1, 2025, 00:00

  • EE617 Procalcitonin-Guided Antimicrobial Stewardship for Sepsis and Lower Respiratory Tract Infections: A Budget Impact Analysis for the Perspective of the Patients in India

    Dec 1, 2025, 00:00

  • HSD79 Optimizing Workforce Efficiency and Reducing Waiting Lists Through Remote Monitoring in Obstructive Sleep Apnea (OSA) Care in NHS

    Dec 1, 2025, 00:00

  • MSR47 BHM and BHM-Based Extrapolations in an HTA Framework

    Dec 1, 2025, 00:00

  • EE418 Estimating Costs Avoided by Preventing Recurrences With a BRCA Testing Strategy in High-Risk HER2-Negative Adjuvant Breast Cancer Patients in Spain

    Dec 1, 2025, 00:00

  • EE439 Evaluating the Costs of Perioperative Iron-Deficiency Anemia Management in China: A Comparison of Ferric Derisomaltose, Ferric Carboxymaltose, and Usual Care

    Dec 1, 2025, 00:00

  • HPR216 The Value of Rare Pediatric Disease Designation Program for Decision Making by Drug Developers

    Dec 1, 2025, 00:00

  • EE50 Analysis of Social and Economic Burden of Type 1 Diabetes Care in Italy

    Dec 1, 2025, 00:00

  • HTA92 Cost-Effectiveness Analysis of Aztreonam Avibactam (ATMAVI) ± Metronidazole (MTZ) for the Treatment of Complicated Intra-Abdominal Infections (cIAIs) and Ventilator-Associated Hospital-Acquired Pneumonia (HAP/VAP) Caused by Suspected ...

    Dec 1, 2025, 00:00

  • CO91 Efficacy and Safety of Biologics to Treat Adults With Active Radiographic Axial Spondyloarthritis: Systematic Review and Bayesian Network Meta-Analysis

    Dec 1, 2025, 00:00

  • CO199 Real Option Value of Sotatercept in Pulmonary Arterial Hypertension: A Health Economic Perspective on Future Treatment Opportunities

    Dec 1, 2025, 00:00

  • CO40 Characterization of the Distribution of Body Mass Index in Portuguese People With Type 2 Diabetes

    Dec 1, 2025, 00:00

  • PCR98 Factors Influencing Intent to Vaccinate Against Respiratory Syncytial Virus (RSV) Among Older Adults in Australia, Hong Kong, Japan, New Zealand, South Korea, Singapore, and Taiwan

    Dec 1, 2025, 00:00

  • HPR53 Deliverables From 10 Years' Implementation of a National Health Technology Assessment System: Outcomes Sustainability Efficiency, Access, and Equity

    Dec 1, 2025, 00:00

  • EE64 Assessing the Value of Purewick™ System for the Management of Female Patients With Urinary Incontinence in the Nonacute Setting: Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • HPR119 Implementing Coverage With Evidence Development for Medicines With Uncertain Clinical Benefit: Insights From the Netherlands

    Dec 1, 2025, 00:00

  • EE636 Real-World Evidence on Healthcare Resource Utilization (HCRU) and Economic Burden of Patients With COPD Treated With Dual or Triple Therapy: Stratified Analysis by Blood Eosinophil Count and Exacerbation Phenotype in the BREATHE-IN St ...

    Dec 1, 2025, 00:00

  • HTA322 The Key Role of Social Participation in Health Technology Assessment: Experiences From South American Countries

    Dec 1, 2025, 00:00

  • SA11 An AI-Enhanced Targeted Literature Review Workflow to Support Inclusive Research Practices and Population Science Research: A Human-in-the-Loop Approach

    Dec 1, 2025, 00:00

  • HPR34 Barriers and Policy Solutions in Off-Patent Drug Repurposing: A Full-Life-Cycle Perspective

    Dec 1, 2025, 00:00

  • CO234 The Association of Glucagon-Like Peptide-1 Receptor Agonists With Hepatopancreatobiliary Diseases in Individuals With Type 2 Diabetes Mellitus

    Dec 1, 2025, 00:00

  • RWD125 Millennial Medical Record (MMR) Data Profile: A Japanese Electronic Medical Records (EMRs) Database Utilizing Unstructured Data for Lung Cancer Research

    Dec 1, 2025, 00:00

  • PCR64 Development of Two Versions of a Patient-Reported Outcome Measure to Evaluate Participant Experience and Satisfaction During the Intervention and Analytical Treatment Interruption Periods of Cure-Related and Other HIV Trials

    Dec 1, 2025, 00:00

  • RWD68 Economic and Clinical Burden of MACE-Related Rehospitalizations in Patients With Obesity: A Real-World Study Based on Italian Healthcare Data

    Dec 1, 2025, 00:00

  • HPR154 Patient Pathways to Accessing Unregistered Medicines in Low-Priority Launch Markets

    Dec 1, 2025, 00:00

  • MSR165 Performance Evaluation of AI-Assisted Systematic Literature Review for Studies on Burden of HPV-Associated Head and Neck Cancers

    Dec 1, 2025, 00:00

  • EE113 Budget Impact of the VELYS™ Robotic-Assisted Solution Compared to Manual Procedure in Patients Undergoing Primary Total Knee Arthroplasty in Italy

    Dec 1, 2025, 00:00

  • EE576 Medium vs. Low Citrate Concentration in Continuous Kidney Replacement Therapy: Positive Budget Impact Through Total Cost of Ownership Assessment

    Dec 1, 2025, 00:00

  • HTA63 Building the Bridge to Access: Leveraging RWE From Early Access Schemes to Reimbursement in Gene and Cell Therapies

    Dec 1, 2025, 00:00

  • PCR230 The Estimation of Utility Weights From the Rett Syndrome Behavior Questionnaire

    Dec 1, 2025, 00:00

  • MSR145 Measuring the Elephant in the Room: Quantifying Legal Barriers to AI Processing of Full-Text in Systematic Reviews

    Dec 1, 2025, 00:00

  • PT13 Mapping the Measurement Gap: Patient-Reported Outcomes Across the Obesity Care Continuum in the GLP-1 Era

    Dec 1, 2025, 00:00

  • HTA64 Canadian HTA Decisions (2020-2023): Comparing CDA-AMC and INESSS Recommendations on Drug Reimbursement

    Dec 1, 2025, 00:00

  • HPR181 Semaglutide in Transition: A Nationwide Register-Based Study in Finland 2019-2024

    Dec 1, 2025, 00:00

  • SA105 Where Is AI in Evidence Synthesis for NICE HTA Submissions?

    Dec 1, 2025, 00:00

  • EE226 Cost-Effectiveness and Impact of Nirmatrelvir/Ritonavir in Reducing Hospitalizations Among Elderly COVID-19 Patients in Sweden

    Dec 1, 2025, 00:00

  • EE378 Economic Evaluation of Contemporary First-Line (1L) Treatments for Locally Advanced or Metastatic Urothelial Carcinoma La/mUC in Fran A Sensitivity Analysis

    Dec 1, 2025, 00:00

  • EE55 Assessing Conditional Cash Transfers for Tuberculosis Patients in India: An Extended Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • PCR99 Framing Matters! Implications of Loss Aversion for Communicating Benefits to Patients in Preference Studies (and Beyond)

    Dec 1, 2025, 00:00

  • HPR13 Acceptance of Clinical Studies Conducted in Nonus Settings by the FDA Based on the Analysis of Selected Novel Drug Approvals

    Dec 1, 2025, 00:00

  • P37 Advancing Preference Elicitation Techniques for Rare Diseases and Limited Sample Populations

    Dec 1, 2025, 00:00

  • SA60 Let LAMBA Do the Work: Can We Reduce Reliance on VBA in Health Economic Models?

    Dec 1, 2025, 00:00

  • MSR164 Patients With Lupus Across Germany: An AI/ML Driven Method to Maximize Patient Selection From Longitudinal Prescription Data (IQVIA LRx)

    Dec 1, 2025, 00:00

  • EE589 Modeling the Healthcare Burden of Oral Corticosteroid Use in Mexico

    Dec 1, 2025, 00:00

  • HTA212 Is Protocolized Stopping Lifelong Therapy With Eculizumab With Disease Monitoring and Retreatment for Eligible Atypical Hemolytic Uremic Syndrome (aHUS) Patients Cost-Effective? An Economic Evaluation of the SETS aHUS Trial

    Dec 1, 2025, 00:00

  • Dec 1, 2025, 00:00

  • EE224 Cost-Effectiveness and Budget Impact of Increasing Peritoneal Dialysis Utilization Among End-Stage Kidney Disease Patients in South Korea

    Dec 1, 2025, 00:00

  • EE40 Adherence to Guidelines for the Treatment of Diabetes With Modern Antidiabetic Drugs in the Czech Republic: Clinical and Economic Impacts

    Dec 1, 2025, 00:00

  • CO78 Dupilumab Improves Lung Function and Asthma Control While Reducing Systemic Corticosteroid Use in Patients With Allergic Bronchopulmonary Aspergillosis: The Phase 2 LIBERTY ABPA AIRED Study

    Dec 1, 2025, 00:00

  • EE375 Economic Evaluation of Bispecific Antibodies in Europe: A Systematic Review

    Dec 1, 2025, 00:00

  • EPH66 Durable Medical Equipment and Ancillary Service Use in Rett Syndrome Management: A Global Comprehensive Review of Literature

    Dec 1, 2025, 00:00

  • RWD32 Characterizing Comorbidities and Co-Occurring Conditions in Adults with Generalized Anxiety Disorder in the United States

    Dec 1, 2025, 00:00

  • PCR218 Social Media Listening Analysis of Cannabis Use in Patients With Inflammatory Bowel Disease

    Dec 1, 2025, 00:00

  • MSR160 Optimizing Patient-Reported Outcomes in German HTA: Addressing Key Challenges and Methodological Requirements

    Dec 1, 2025, 00:00

  • RWD87 From Data to Decisions: Enhancing Real-World Data Quality: A Survey of Health Data Producers in France

    Dec 1, 2025, 00:00

  • MSR190 Structured Expert Elicitation for Survival Outcomes: Insights From NICE Technical Support Document 26

    Dec 1, 2025, 00:00

  • EPH189 Prevalence of Meningococcal Carriage by Serogroup in Adolescents and Young Adults: A Global Systematic Literature Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • EE501 Healthcare Costs of Mammography Screening and Breast Cancer Treatment: A Registry-Based Study From Norway

    Dec 1, 2025, 00:00

  • MT22 Global Evaluation of Flexible Cysto-Nephroscope Usage Patterns in Percutaneous Nephrolithotomy Procedures

    Dec 1, 2025, 00:00

  • EE684 Technical Validation of Health Economic Models: Is There a Gold Standard? Assessment and Refinement of Current Checklist Tools

    Dec 1, 2025, 00:00

  • PCR74 Enhancing Patient Experience of Subcutaneous Administration in Oncology: Development of a Dedicated Patient-Reported Experience Measure (PREM) Questionnaire Based on a Structured and Collaborative Approach

    Dec 1, 2025, 00:00

  • HTA81 Comparing Clinical Benefit Criteria in Health Technology Assessment of Oncology Drugs in the Netherlands and Europe: Driving Real Value or Inequal Access?

    Dec 1, 2025, 00:00

  • CO101 Estimating the Long-Term Impact of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Treatments on the Annual Decline of Percent-Predicted Forced Expiratory Volume in One Second (ppFEV1) Compared to Established Clin ...

    Dec 1, 2025, 00:00

  • RWD99 Identification of Real-World Data to Study HAE Unmet Need: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • HTA191 Identifying Methods Used Within Early Value Assessments for NICE: Results of a Scoping Review

    Dec 1, 2025, 00:00

  • EPH239 The Health Impact of Pembrolizumab in Combination With Chemotherapy for the First-Line Treatment of Patients With Squamous Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Türkiye

    Dec 1, 2025, 00:00

  • CO26 Bayesian Dynamic Borrowing to Enhance Evidence for New Therapies

    Dec 1, 2025, 00:00

  • HTA315 The Elusive PICO: Assessing Prediction in Joint Clinical Assessments (JCA): A Case Study in Soft Tissue Sarcoma (STS)

    Dec 1, 2025, 00:00

  • SA15 Balancing Rigor and Feasibility of Real-World Data Demands in Germany Within the EU HTA Context: How Fit for Purpose Is the Routine Practice Data Collection (Anwendungsbegleitende Datenerhebung, AbD)?

    Dec 1, 2025, 00:00

  • CO126 Gene Expression Profiling Tests to Guide Adjuvant Chemotherapy Decisions in Lymph Node-Positive Early Breast Cancer: A Systematic Review

    Dec 1, 2025, 00:00

  • HTA226 Long-Term HTA Trends in Patient Organization Submissions to the NCPE and Future Perspectives

    Dec 1, 2025, 00:00

  • HTA43 Artificial Intelligence-Based Population, Intervention, Comparator, and Outcome (PICO) Prediction for European Union (EU) Joint Clinical Assessment (JCA)

    Dec 1, 2025, 00:00

  • MSR72 Development of an AI-Powered Tool to Accelerate and Enhance Systematic Literature Reviews for Evidence-Based Decision Making in Clinical Research

    Dec 1, 2025, 00:00

  • HTA192 IMF: The Innovative Medicines Fund or the Interim Medicines Fund?

    Dec 1, 2025, 00:00

  • MSR214 Using Directed Acyclic Graphs in Matching-Adjusted Indirect Comparison and Simulated Treatment Comparison: Systematic Review and Methodological Insights

    Dec 1, 2025, 00:00

  • HTA309 Systematic Review of Value Assessment Frameworks for Digital Health Interventions: Toward a Multidimensional Evaluation Approach

    Dec 1, 2025, 00:00

  • HTA337 Too Advanced for STA, Too Common for HST? Navigating NICE Appraisals of Gene Therapies

    Dec 1, 2025, 00:00

  • PCR23 Assessing the Sensitivity of EQ-5D-5L and AQoL-4D to Disease Severity in Von Willebrand Disease: Findings From UK Cohort of the PIVOT-vWD Study

    Dec 1, 2025, 00:00

  • HTA41 Are Women’s Health Strategies Driving Change? A Review of NICE and SMC HTAs

    Dec 1, 2025, 00:00

  • SA103 What Makes a Medicine Innovative? A Literature Review of Evaluation Frameworks

    Dec 1, 2025, 00:00

  • HTA99 Costs and Their Impacts That Should Be Included in Health Technology Assessment of Remote Palliative Care

    Dec 1, 2025, 00:00

  • EPH238 The Health Impact of Pembrolizumab in Combination With Chemotherapy for the First-Line Treatment of Patients With Nonsquamous Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Türkiye

    Dec 1, 2025, 00:00

  • EE231 Cost-Effectiveness Model of Ranolazine for Treating Chronic Stable Angina Patients From Kingdom of Saudi Arabia Perspective

    Dec 1, 2025, 00:00

  • MSR176 Q-Squared as a Mapping Model Performance Metric in Gastrointestinal Disease

    Dec 1, 2025, 00:00

  • EE166 Cost Effectiveness and Budget Impact Analysis of Benralizumab for Treating Severe Uncontrolled Eosinophilic Asthma in Egypt

    Dec 1, 2025, 00:00

  • HSD104 Strengthening Routine Childhood Immunization Post-COVID: Global Strategies to Improve Coverage and Equity

    Dec 1, 2025, 00:00

  • CO164 Mind the Gap: A Need for Guidance on Modeling Disease Activity Outcomes in Economic Models

    Dec 1, 2025, 00:00

  • HSD14 Biologic Treatment Patterns and Phenotyping in Severe Uncontrolled Asthma: A Multinational Study

    Dec 1, 2025, 00:00

  • Inequality Aversion in Health: Eliciting Aversion to Univariate Health Inequalities Across Different Health Distributions

    Dec 1, 2025, 00:00

  • MT18 From Development to Reimbursement Evidence-Generation Strategies for HealthTech in Europe

    Dec 1, 2025, 00:00

  • EPH177 Perspectives on Progress: A Qualitative Study of HIV Prevention Efforts in the Czech Republic

    Dec 1, 2025, 00:00

  • RWD59 Development and Evaluation of a Proactive Monitoring Model for Adverse Drug Events in Patients With Pulmonary Arterial Hypertension Based on the Delphi and Real-World Data

    Dec 1, 2025, 00:00

  • CO183 Potential Benefits of Universal Influenza Vaccination on Health Outcomes and Costs in Mexico

    Dec 1, 2025, 00:00

  • RWD108 Integrating Agentic AI With LLM Workflows for Cohort Comparison in Healthcare Analytics

    Dec 1, 2025, 00:00

  • EPH234 The Estimation of the Prevalent Presymptomatic Type 1 Diabetes Population in Germany Using a Patient Funnel Model

    Dec 1, 2025, 00:00

  • EPH233 The Epidemiology Burden and Management of Chronic Hand Eczema in Adolescents: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • SA57 Internal Validation of Type 2 Diabetes and Cardiovascular Events Incidences in the Core Obesity and Diabetes Model

    Dec 1, 2025, 00:00

  • EE530 Impact Of Dupilumab Treatment On Healthcare Resource Utilization in Patients With Atopic Dermatitis in a Colombian Health Insurance Provider: An Observational Real-World Practice Study

    Dec 1, 2025, 00:00

  • EE538 Impact of Nirsevimab on the Health Burden and Costs of Respiratory Syncytial Virus (RSV) in the Infant Population From the Healthcare System in Argentina

    Dec 1, 2025, 00:00

  • HPR84 Evolving Trends in US Healthcare Policy: Perspectives From US Formulary Decision Makers

    Dec 1, 2025, 00:00

  • HSD95 Real-World Hospital Stays Description and Cost Analysis of Immune Checkpoint Inhibitors (ICIs) Using National PMSI Data in France

    Dec 1, 2025, 00:00

  • HTA44 Assessing Readiness for the EU-HTA Regulation: Insights From Market Access Experts Across Europe

    Dec 1, 2025, 00:00

  • EE297 Cost-Utility Analysis of Adding Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors or Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists to Standard Therapy in Thai Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Diseas ...

    Dec 1, 2025, 00:00

  • CO184 Predictors of Postoperative Complications Following Cytoreductive Surgery With HIPEC: A Real-World Analysis of 493 Patients in Québec

    Dec 1, 2025, 00:00

  • EE107 Budget Impact of Including Cannabis-Based Products in Brazil’s Public Health System: A Scenario Analysis

    Dec 1, 2025, 00:00

  • RWD103 Incidence of Adverse Events and Costs Among Patients Initiating Treatment for Myasthenia Gravis: A Real-World Analysis

    Dec 1, 2025, 00:00

  • EE39 Addressing the Impact of Alzheimer’s Disease on Care Capacity in the Netherlands: Implications for Health Technology Assessment

    Dec 1, 2025, 00:00

  • EE4 A Budget Impact Model of Switching From Self-Monitoring of Blood Glucose to Continuous Glucose Monitoring for Individuals With Type 2 Diabetes Mellitus Receiving Basal Insulin in Italy

    Dec 1, 2025, 00:00

  • PCR148 Listening to the Voice of the Patient: Insights From a Survey on the Burden of Recurrent Respiratory Papillomatosis in the United States

    Dec 1, 2025, 00:00

  • EE100 Budget Impact Analysis of the EPOCA Telemonitoring System for Elderly Patients in France

    Dec 1, 2025, 00:00

  • SA55 Innovative Approaches to Real-World Evidence Generation: The Role of Italian Community Pharmacies

    Dec 1, 2025, 00:00

  • EE200 Cost-Effectiveness Analysis of FreeStyle Libre Systems vs. Self-Monitoring of Blood Glucose in People With Type 2 Diabetes on Basal Insulin: An Israeli Healthcare System Perspective

    Dec 1, 2025, 00:00

  • EE376 Economic Evaluation Of Cefiderocol for the Treatment of Carbapenem-Resistant Acinetobacter Baumannii in Italy Using Real-World Evidence

    Dec 1, 2025, 00:00

  • Zero Dollar Copay Pharmacy Benefit Decreases Healthcare Expenditures Among Members With Type 2 Diabetes of Blue Cross Blue Shield of Louisiana

    Dec 1, 2025, 00:00

  • EE17 A Cost-Utility Analysis of Sparsentan for the Treatment of Immunoglobulin A Nephropathy in the UK

    Dec 1, 2025, 00:00

  • PCR153 Meaningful Within-Patient Change of the IWQOL-Lite-CT Physical Function Composite in Adults With Obesity

    Dec 1, 2025, 00:00

  • EE14 A Cost-Minimization and Budget Impact Analysis of NT-proBNP Screening for Systematic Sclerosis-Related Pulmonary Arterial Hypertension in an Australian Healthcare Setting

    Dec 1, 2025, 00:00

  • P53 Exploring the Ability of Generative AI to Interpret and Report Comprehensive NMA Results: A Step Towards the Automation of NMA Reports

    Dec 1, 2025, 00:00

  • EE543 Impact of Temporarily Implanted Nitinol Device in the Treatment of Urinary Symptoms in Patients With Benign Prostatic Obstruction in Spain

    Dec 1, 2025, 00:00

  • SA34 Direct Healthcare Costs (HCCs) Inequalities Associated With Myasthenia Gravis (MG) in Hungary: Claims Database Analysis

    Dec 1, 2025, 00:00

  • P17 Implementation of Patient Experience Data in Clinical Trial Design: A Literature Review and Semi-Structured Interviews

    Dec 1, 2025, 00:00

  • EPH215 Site-Specific Wastewater-Based Surveillance in Early Detection of COVID-19 New Cases and Prediction of Mass Testing Outcomes in Long-Term Care Facilities

    Dec 1, 2025, 00:00

  • EE15 A Cost-Minimization and Budget Impact Analysis of NT-proBNP Screening Test for Risk Assessment and Monitoring of Pulmonary Arterial Hypertension (PAH) Patients in Australian Healthcare Setting

    Dec 1, 2025, 00:00

  • The Impact of the Inflation Reduction Act’s Drug Price Negotiation Program on Incentives for Clinical Development of New Drugs

    Dec 1, 2025, 00:00

  • HTA65 Caregiver Quality of Life in Orphan Drug Health Technology Assessment Submissions in Europe: A Comparative Analysis

    Dec 1, 2025, 00:00

  • EE552 Indirect Treatment Comparisons in Economic Evaluations Submitted to the French Health Authority (CEESP) Since 2014

    Dec 1, 2025, 00:00

  • EE102 Budget Impact and Clinical Outcomes of Energy- and Nutrient-Dense Formulas in Pediatric Disease-Related Malnutrition: A Middle Eastern Analysis

    Dec 1, 2025, 00:00

  • EPH59 Development and Validation of a Case Identification Algorithm for Hand Trauma Patients Using Health Administrative Data and the Epidemiology of Hand Trauma in a Universal Healthcare System

    Dec 1, 2025, 00:00

  • EPH224 Survival Trends in Multiple Myeloma by Treatment Era in the United States

    Dec 1, 2025, 00:00

  • EE715 The Impact of Real-World Standard-Dose Influenza Vaccine Effectiveness on the Cost-Effectiveness of High-Dose Influenza Vaccine: A Case Study in Japan

    Dec 1, 2025, 00:00

  • P27 Predicting Treatment Effect on the Loss of Ability to Rise From Floor in Duchenne Muscular Dystrophy Using Individual Trajectories: An Application of Joint Modeling in FOR-DMD

    Dec 1, 2025, 00:00

  • EE421 Estimating Life-Years and QALYs Gained From Tumor Treating Fields in Newly Diagnosed Glioblastoma: A US-Based Real-World Survival-Based Model

    Dec 1, 2025, 00:00

  • MSR24 AI-Driven Simulation of FDA DCOA Review to Inform Evidence Planning and Regulatory Strategy

    Dec 1, 2025, 00:00

  • MSR120 How Chinese Restaurants Can Help With Robust Preference Insights: A Novel Dirichlet Mixture Model to Account for Complex Heterogeneity in Individual Preference Weights

    Dec 1, 2025, 00:00

  • CO223 Symptom Relief With Vonoprazan Treatment in Gastroesophageal Reflux Disease Patients With Diabetes in China: Post Hoc Analysis of the VIEW Study

    Dec 1, 2025, 00:00

  • HTA271 Predicting PICOs for EU HTA: The Validated PICO Planner Approach Based on Retrospective Analysis

    Dec 1, 2025, 00:00

  • HSD96 Real-World Study on Length of Hospital Stay and Economic Burden of AECOPD Inpatients in a Traditional Chinese Medicine Hospital in China

    Dec 1, 2025, 00:00

  • PCR175 Patient Perspectives on the Lifelong Impact of Preterm Birth in Chronic Respiratory Disease Care

    Dec 1, 2025, 00:00

  • HTA267 Patient-Centered Hearing Technology Assessment: Integrating ICF Into Multicriteria Decision Making

    Dec 1, 2025, 00:00

  • SA37 Effectiveness of Psychosocial Interventions for Adults With Substance Use Disorder and Co-Occurring Mental Health Disorder: An Umbrella Review

    Dec 1, 2025, 00:00

  • EE229 Cost-Effectiveness Evaluation of Combined Cervical Cancer Screening With CINtec PLUS in the Czech Republic

    Dec 1, 2025, 00:00

  • HPR131 Launches of Oncology Products in LATAM vs. the United States

    Dec 1, 2025, 00:00

  • HPR193 The Alignment Between Technology Incorporations and Actual Health Needs

    Dec 1, 2025, 00:00

  • CO80 Early Life Hypoglycemia and Neurological Sequalae in Children With Congenital Hyperinsulinism

    Dec 1, 2025, 00:00

  • EE195 Cost-Effectiveness Analysis of CYP2C19 Genotype-Guided Antiplatelet Therapy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in the Netherlands

    Dec 1, 2025, 00:00

  • PCR261 Utilizing the Patient-Specific Needs Evaluation for Data-Supported and Individualized Treatment (UNITE)

    Dec 1, 2025, 00:00

  • EE452 Exit Strategies in Patients With Stable MS: Cost-Effectiveness of Extended Interval Dosing of Ocrelizumab and Natalizumab vs. De-escalating to Cladribine

    Dec 1, 2025, 00:00

  • EE56 Assessing Productivity in Health Technology Assessment: A Comparative Review of Human Capital and Friction Cost Approaches in Europe

    Dec 1, 2025, 00:00

  • MSR207 Turning the Tables: AI Halves Table Extraction Time in HEOR Systematic Reviews

    Dec 1, 2025, 00:00

  • EPH87 Estimating the Eligible Population for Anti-Amyloid Therapy in Finland

    Dec 1, 2025, 00:00

  • CO173 OncoLlama: Quantifying Cancer Inequalities at Population Scale Using Large Language Models for Clinical Text Abstraction

    Dec 1, 2025, 00:00

  • HTA351 Use of the ESMO-Magnitude of Clinical Benefit Scale to Guide HTA Recommendations on Coverage and Reimbursement for Cancer Medicines in Ireland: A Retrospective Analysis

    Dec 1, 2025, 00:00

  • EE438 Evaluating the Cost-Effectiveness of Nasal Adrenaline Spray vs. Adrenaline Autoinjector for Treatment of Anaphylaxis: A Cost-Utility Modeling Approach

    Dec 1, 2025, 00:00

  • EE287 Costs and Number Needed to Treat (NNT) to Achieve Improvements With C5 Inhibitors in Generalized Myasthenia Gravis From the Japanese Healthcare Perspective: A Network Meta-Analysis

    Dec 1, 2025, 00:00

  • HTA136 Evaluating the Value Elements Considered in Health Technology Assessments of Paroxysmal Nocturnal Hemoglobinuria Treatments: A Targeted Review

    Dec 1, 2025, 00:00

  • RWD61 Development and Implementation of a Health and Well-being Index to Inform Risk Management and Patient Engagement in a Colombian Health Insurance Plan

    Dec 1, 2025, 00:00

  • HTA66 CAR-T Therapy in Asia-Pacific: Is It Reimbursed in Your Country?

    Dec 1, 2025, 00:00

  • PT12 Understanding the Consequences of International Reference Pricing on Cancer Immunotherapy in Europe: A 10-Year Price Corridor Analysis

    Dec 1, 2025, 00:00

  • PT41 Health Economic Evaluations of Prevention and Management Strategies for Cholangiocarcinoma: A Systematic Review

    Dec 1, 2025, 00:00

  • EPH275 Urinary Dysfunction Management in Multiple Sclerosis: A Nationwide Real-Life Analysis From the French SNDS Database

    Dec 1, 2025, 00:00

  • EPH240 The Health Impact of Pembrolizumab Plus Chemotherapy in the First-Line Treatment for Metastatic Triple-Negative Breast Cancer (TNBC) in Türkiye

    Dec 1, 2025, 00:00

  • PCR20 Are You Implementation Ready? An Alternative Patient And Healthcare System-Centered Model For Pharma

    Dec 1, 2025, 00:00

  • HTA116 The Challenges of Evaluating Individualized Therapies in Health Technology Assessment: A Thematic Review

    Dec 1, 2025, 00:00

  • EE758 Work Complexity in Adults With Phenylketonuria in Sweden in 2020

    Dec 1, 2025, 00:00

  • EPH113 Fostamatinib-Induced Hepatomegaly: A Novel Signal Identified Through US Food and Drug Administration Adverse Event Reporting System (FAERS) Database

    Dec 1, 2025, 00:00

  • HPR173 Regulatory Landscape Challenges and Trends in the Adoption of Digital Endpoints in Clinical Trials: A Scoping Review

    Dec 1, 2025, 00:00

  • HPR199 The Enduring Economic Burden of COVID-19 and the Value of Vaccination Strategies in High-Income Countries

    Dec 1, 2025, 00:00

  • CO116 Expert Consensus on the Clinical and Economic Value of Advanced Wound-Care Products in Mexico: Results From a Delphi Panel

    Dec 1, 2025, 00:00

  • HTA147 Focus on Two Years of Economic Opinions on Solid Cancers (2023-2024): What Are the Specific Features vs. 2021-2022?

    Dec 1, 2025, 00:00

  • EE154 Correlation Between Ultra-Orphan Drug Costs Cost-Effectiveness Metrics and Disease Prevalence

    Dec 1, 2025, 00:00

  • EE353 Economic Burden and Health-Related Quality of Life Associated With Schizophrenia in Saudi Arabia

    Dec 1, 2025, 00:00

  • HPR32 Balancing Cost-Effectiveness With Societal Values: A Representative Survey of Norwegian Attitudes Toward Healthcare Resource Allocation

    Dec 1, 2025, 00:00

  • EE498 Healthcare Burden Among Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE24 A Nonactive Implant for the Treatment of Chronic Gastro-esophageal Reflux Disease: A Cost-Effectiveness Evaluation From the Perspective of German Healthcare

    Dec 1, 2025, 00:00

  • HSD73 Medication Patterns of Traditional Chinese Medicine for Chronic Obstructive Pulmonary Disease: A Real-World Data Analysis

    Dec 1, 2025, 00:00

  • HSD92 Real-World Analysis of Treatment Patterns and Disease Exacerbations Among Patients Initiating Therapy for Myasthenia Gravis

    Dec 1, 2025, 00:00

  • HTA357 Vignette-Based Economic Models in UK HTA Submissions: Valuable Tool or Just NICE in Theory?

    Dec 1, 2025, 00:00

  • EE547 Improving the Transferability of Global RCT Data to Inform Cost-Effectiveness Models in Japan: A Structured Framework for C2H Submissions

    Dec 1, 2025, 00:00

  • PCR94 Exploring the Promise of Generative AI for Coding and Analyzing Qualitative Patient Data: Results From a Pilot Study in Non-Hodgkin’s Lymphoma

    Dec 1, 2025, 00:00

  • MSR21 AI-Assisted Systematic Literature Screening According to NICE, UK, and CDA (Canada) Position Papers: An HTA Submission Use Case

    Dec 1, 2025, 00:00

  • MSR69 Developing an HER-Based Multifeature Machine Learning Model to Identify Lung Cancer Subtype

    Dec 1, 2025, 00:00

  • MSR75 AI Time and Motion - Analysis of the Accuracy and Efficiency of AI for HTA-Standard SLRs

    Dec 1, 2025, 00:00

  • HSD90 Potential Operational Efficiencies of a Combination Influenza and COVID-19 Vaccine in US Pharmacies

    Dec 1, 2025, 00:00

  • EE604 Organizational Budget Impact Analysis of the Port-Delivery Platform With SUSVIMO in Age-Related Macular Degeneration (AMD) in France

    Dec 1, 2025, 00:00

  • CO84 Effective Use of Reconstructed Survival Data for Individual-Level Correlation Assessment in Oncology: A Case Study in Metastatic-Hormone Sensitive Prostate Cancer (mHSPC)

    Dec 1, 2025, 00:00

  • SA2 A Patient-Level Simulation to Bridge Data Gaps in Cost-Effectiveness Modeling of B-VEC for Dystrophic Epidermolysis Bullosa

    Dec 1, 2025, 00:00

  • PCR199 Qualitative Assessment of Women’s Experiences of Sleep Disturbances Associated With Menopause to Evaluate Content Validity of Patient-Reported Outcomes

    Dec 1, 2025, 00:00

  • EE671 Stakeholder Engagement in the Economic Evaluation of Site-Specific Wastewater-Based Surveillance for Preventing COVID-19 Outbreaks in Long-Term Care Facilities

    Dec 1, 2025, 00:00

  • MSR125 Human Alignment on Evaluating LLMs for Literature Review Extraction

    Dec 1, 2025, 00:00

  • HTA358 Weighting the OrPhar-SEFH MCDA Framework for Its Use in Ultrarare Kidney Diseases

    Dec 1, 2025, 00:00

  • EE598 Optimal Utilization of Robotic-Assisted Surgery in the NHS: A System-Level Economic Evaluation Model

    Dec 1, 2025, 00:00

  • EE453 Expanded Access to Oncology Therapies in Mexico: The Role of Bioequivalent Abiraterone and Axitinib

    Dec 1, 2025, 00:00

  • RWD123 Medication Use in Indolent Systemic Mastocytosis (ISM) in Germany Prior to Avapritinib EMA Approval

    Dec 1, 2025, 00:00

  • SA95 The Journey to Diagnosis for Patients With CIDP: Results From a Real-World International Survey

    Dec 1, 2025, 00:00

  • P7 Life-Cycle Economic Modeling to Determine the Evolving Value of a Tumor-Agnostic Precision Oncology Therapy With Conditional Marketing Authorization

    Dec 1, 2025, 00:00

  • RWD145 Real-World Insights From the LOGEX IMID Observatory: A Multicountry, Multiyear Analysis of Treatment Pathways and Healthcare Resource Utilization in Immune-Mediated Inflammatory Diseases

    Dec 1, 2025, 00:00

  • EE489 Health Economic Assessment of Cefepime-Enmetazobactam for Treating Complicated Urinary Tract Infections: A German Payer Perspective

    Dec 1, 2025, 00:00

  • EE442 Evaluating the Economic Impact of Worksite Physical Activity Interventions in Denmark: An Employer’s Perspective

    Dec 1, 2025, 00:00

  • EE541 Impact of Real-World Effectiveness vs. Previous Assumptions on Estimates of Economic and Clinical Benefit of 20-Valent Pneumococcal Conjugate Vaccine in Adults Across Countries

    Dec 1, 2025, 00:00

  • HPR178 Revisiting the Willingness-to-Pay Threshold in the Czech Republic: Integrating QALY Shortfall to Reflect Disease Severity and Unmet Medical Need

    Dec 1, 2025, 00:00

  • CO36 Cardioprotective Medication Use Among Diabetic Patients With ASCVD in Qatar's Primary Care Setting

    Dec 1, 2025, 00:00

  • MSR186 Simulated Treatment Comparisons Using Jackknife Pseudo Values for Population-Adjusted Marginal Effect Estimation

    Dec 1, 2025, 00:00

  • EE30 A Review of Health Economic Modeling Challenges for Opioid Use Disorder Treatment in Prison Settings

    Dec 1, 2025, 00:00

  • EE556 Inpatient Cost of Managing Adverse Events (AEs) Associated With Immune Checkpoint Inhibitors (ICI) Approved for Advanced or Metastatic Cancers in the UK

    Dec 1, 2025, 00:00

  • EPH88 Estimating the Future Burden of Unvaccinated Girls Against Human Papilloma Virus (HPV) in Europe: A Modeling Study

    Dec 1, 2025, 00:00

  • HPR12 Accelerating Therapeutic Innovation: Early Results From France’s Accès Direct Scheme

    Dec 1, 2025, 00:00

  • EE278 Cost-Effectiveness of Supportive Exercise Interventions for Colorectal Cancer Surgery: An Economic Evaluation of the PREPARE-ABC Multicenter, Randomized, Controlled Trial

    Dec 1, 2025, 00:00

  • PT32 Can Adalimumab Serve as Big Mac Index for Pharmaceutical Prices?

    Dec 1, 2025, 00:00

  • MSR130 Improving Indirect Treatment Comparisons via an Alternative MAIC Patient Weighting Method

    Dec 1, 2025, 00:00

  • HTA27 Advocating From the Margins: How Patient Input Aligns With Broader Evidence Tolerance in HTA Within Oncology

    Dec 1, 2025, 00:00

  • Author Reply

    Dec 1, 2025, 00:00

  • EPH91 Evaluate the Statistical Utility After Transformation of a CDISC SDTM Database Into OMOP CDM

    Dec 1, 2025, 00:00

  • EPH259 Trends and Characteristics of Thrombectomy Use in Acute Ischemic Stroke in Germany (2019-2024): Insights From National Claims Data

    Dec 1, 2025, 00:00

  • CO227 Systematic Literature Review and Bayesian Network Meta-Analysis of Sugemalimab Plus Chemotherapy vs. Other First-Line Treatments for Metastatic Non-Small Cell Lung Cancer Without Sensitizing eGFR, ALK, ROS1, or RET Alterations

    Dec 1, 2025, 00:00

  • CO241 The Impact of Generalized Anxiety Disorder on Comorbid Conditions: A Systematic Review

    Dec 1, 2025, 00:00

  • PCR223 Taking an Equity Lens to Patient-Reported Outcomes and Experiences in Wales Using PROGRESS PLUS: A Population-Based Cross-Sectional Study

    Dec 1, 2025, 00:00

  • MSR31 Applying Simulation-Guided Trial Design Principles to Prospectively Plan Target Trial Emulation of a Cluster Randomized Trial for Vaccine Coverage

    Dec 1, 2025, 00:00

  • HTA285 Reimbursement Trends Across Global Markets in 2024

    Dec 1, 2025, 00:00

  • EE759 Workforce and Environmental Impact of Home-Based vs. Hospital-Based Administration of Second-Line MS Therapies in the Netherlands: A Comparative Analysis of Personnel Time and Carbon Footprint

    Dec 1, 2025, 00:00

  • PCR197 Psychometric Validation of the Mucopolysaccharidosis Health Assessment Questionnaire (MPS-HAQ) for Mucopolysaccharidosis IVA

    Dec 1, 2025, 00:00

  • HSD114 Treatment Characteristics of Breast Cancer Patients per HER2/HR Status in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2018-2022 Database Analysis

    Dec 1, 2025, 00:00

  • HTA181 How the EU JCA Could Interface With Regional Pricing Alliances (BeNeLuxA, Nordic Forum, Valletta Group) and EU-Level Procurement Under the Critical Medicines Act

    Dec 1, 2025, 00:00

  • EE191 Cost-Consequence Analysis of Transjugular Intrahepatic Portosystemic Shunt (TIPS) Treatment vs. Large-Volume Paracentesis (LVP) in the Management of Refractory Ascites: Preliminary Results Overview From an Italian Healthcare Perspecti ...

    Dec 1, 2025, 00:00

  • EE91 Budget Impact Analysis of Noninvasive Tests Strategies for Metabolic Dysfunction-Associated Steatohepatitis (MASH) Diagnosis in Japan

    Dec 1, 2025, 00:00

  • RWD128 Obesity and MASH in the UK

    Dec 1, 2025, 00:00

  • PCR44 CKDL5 Deficiency Disorder: Caregiver’s Perception of Clinical Symptoms Disease Management and Its Impact on Quality-of-life

    Dec 1, 2025, 00:00

  • EPH51 Comparative Prevalence of Suicidal Ideation and Self-Harm History: Rexulti vs. Other Oral Atypical Antipsychotics

    Dec 1, 2025, 00:00

  • HTA76 Clinical Evidence Quality in Appraisals of Drugs for Rare Diseases in England and Germany

    Dec 1, 2025, 00:00

  • HTA246 Navigating Large Evidence Bases for MTEP Submissions

    Dec 1, 2025, 00:00

  • HTA250 Navigating Uncharted Waters: Challenge of Anticipating Technologies Subject to Environmental Considerations in Future HTA

    Dec 1, 2025, 00:00

  • EE198 Cost-Effectiveness Analysis of Fixed-Dose Combination Rosuvastatin and Ezetimibe vs. Simvastatin Plus Ezetimibe for the Treatment of Hypercholesterolemia in Patients at High Risk and Very High Risk of Cardiovascular Disease in Algeria ...

    Dec 1, 2025, 00:00

  • RWD5 A Real-World Survey of Healthcare Resource Utilization Treatment Usage and Unmet Need for Hemophilia Patients in Spain

    Dec 1, 2025, 00:00

  • MSR122 How Far Have We Come With EQ-5D-5L Value Sets? An Updated Systematic Literature Review of 55 Valuation Studies

    Dec 1, 2025, 00:00

  • HPR75 Evaluating the Costs and Benefits of Innovative Pricing and Payment Models in Europe

    Dec 1, 2025, 00:00

  • HTA217 Landscape Analysis of Initiatives to Improve Access to Orphan Drugs Led by Industry Patient and Academic Stakeholders

    Dec 1, 2025, 00:00

  • PCR56 Describing the Burden of RSV Infection and Subsequent Wheezing in Toddlers: An International Cross-Sectional Study

    Dec 1, 2025, 00:00

  • EPH4 A Person-Centered Approach: Exploring Social Support Network and Mental Health Among Shoebox House Residents in Hong Kong

    Dec 1, 2025, 00:00

  • EE481 Global Economic Burden of Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EE313 Cost-Utility of Intramuscular Testosterone for Men and Male Adolescents With Organic Hypogonadotropic Hypogonadism in Brazil

    Dec 1, 2025, 00:00

  • EE140 Comparative Health Economic Evaluation of Alzheimer’s Diagnostic Treatment Strategies in the Era of Amyloid-Targeting Therapies: A Conceptual Model Framework

    Dec 1, 2025, 00:00

  • SA75 Performance of Large Language Model Clinical Data Extraction by Data Domain: A Rapid Systematic Review

    Dec 1, 2025, 00:00

  • EPH10 A Systematic Literature Review to Identify Risk Factors and Symptoms of Long COVID-19 in Adult Indian Patients

    Dec 1, 2025, 00:00

  • HPR140 MCDA Tool Adoption in Egypt: Room for Sustainability and Accessibility

    Dec 1, 2025, 00:00

  • RWD8 Accelerating HEOR Using Petri Net-Based Simulation Informed by Real-World Data

    Dec 1, 2025, 00:00

  • EPH251 The PHEBUS Study: A Retrospective Analysis of the Burden of Pneumococcal Infections in the Pediatric Population Using the French Hospital Discharge Database (PMSI)

    Dec 1, 2025, 00:00

  • HPR239 Which Country Is Currently Reporting the Lowest Global Prices for Semaglutide, and Why?

    Dec 1, 2025, 00:00

  • CO27 Bayesian Network Meta-Analysis of Weight Loss Efficacy for GLP-1 Receptor Agonists and Tirzepatide

    Dec 1, 2025, 00:00

  • HTA59 Budget Impact Analysis Of Migalastat Incorporation vs. Enzyme Replacement Therapies For Fabry Disease: Validation of a Cost-Assessment Tool In Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • OP18 Overview of Hospital Management of Patients Treated With Thoracic Endovascular Repair (TEVAR) and Revascularization of the Left Subclavian Artery in France Based on the PMSI

    Dec 1, 2025, 00:00

  • PCR83 Evaluating the Role of Disease-Specific Patient-Reported Outcomes in HTA Submissions for Rare Conditions: A Comparative Case Study of Narcolepsy and Phenylketonuria

    Dec 1, 2025, 00:00

  • EE161 Cost-Effectiveness Analysis of Ga-PSMA-11 PET/CT Imaging Followed by Lu-PSMA-617 vs. Standard of Care in Metastatic Castrate-Resistant Prostate Cancer

    Dec 1, 2025, 00:00

  • EE383 Economic Evaluation of Second-Generation Colon Capsule Endoscopy for Investigation of the Colon Through Direct Visualization

    Dec 1, 2025, 00:00

  • HTA318 The HTA Landscape of Orphan Products in the UK Between 2019 and 2024

    Dec 1, 2025, 00:00

  • HPR105 From Promise to Practi Addressing the Systemic Challenges of Underinvestment in Prevention

    Dec 1, 2025, 00:00

  • EE180 Cost of First-Line Treatment of Hepatocellular Carcinoma With the Immune Checkpoint Inhibitor-Based Regimens STRIDE and Atezolizumab Plus Bevacizumab in Brazil

    Dec 1, 2025, 00:00

  • SA44 From Participation to Partnership: Advancing Patient-Centric Inclusive and Equitable Evidence Generation in HEOR

    Dec 1, 2025, 00:00

  • PCR67 Effectiveness of Vonoprazan on Health-Related Quality of Life and Sleep Quality in Chinese Patients With Reflux Esophagitis: Post Hoc Analysis of the VIEW Study

    Dec 1, 2025, 00:00

  • EPH156 Large Language Model (LLM) as Catalyst for Rapid and Efficient Critical Appraisal of Epidemiological Research

    Dec 1, 2025, 00:00

  • SA47 Global Trade Shocks and Exchange Rate Effects on Pharmaceutical Reference Pricing: Implications of EU Stimulus for US MFN Policy

    Dec 1, 2025, 00:00

  • MT45 Use of AI in Breast Cancer Screening in England Has a Minimal Impact on Greenhouse Gas Emissions and May Increase Diagnostic Accuracy

    Dec 1, 2025, 00:00

  • EPH194 Productivity Costs Due to Respiratory Infections in Denmark: A Potential for Prophylaxis

    Dec 1, 2025, 00:00

  • EE293 Cost-Savings Assessment of Fitusiran Prophylaxis in Minimizing Breakthrough Bleeding Treatment Expenses in the United Arab Emirates

    Dec 1, 2025, 00:00

  • EE677 Systematic Literature Review of the Use of Generative AI in Health Economic Evaluation

    Dec 1, 2025, 00:00

  • EE694 The Cost-Effectiveness of Targeted-Release Form (TRF)-Budesonide for the Treatment of Adult Population With Immunoglobulin A Nephropathy (IgAN) in Greece

    Dec 1, 2025, 00:00

  • CO56 Comparative Efficacy of Asciminib vs. Second-Generation TKIs in Newly Diagnosed PhCML Using Unanchored Matching-Adjusted Indirect Comparisons

    Dec 1, 2025, 00:00

  • EPH208 Respiratory Syncytial Virus (RSV) Knowledge and Perceived RSV Risk Groups Amongst GP/PCPs and Specialists in APAC: A Cross-Sectional Knowledge Attitude and Practices Survey (RESVIKAP)

    Dec 1, 2025, 00:00

  • MSR107 Facilitator-Led vs. Remote Components Within Structured Expert Elicitation of Survival Outcomes: A Targeted Review

    Dec 1, 2025, 00:00

  • MSR111 From Complex Statistics to Clinically Meaningful Insights: Interpreting Results in Meta-Analyses of Continuous Outcomes

    Dec 1, 2025, 00:00

  • HPR57 Distributional Cost-Effectiveness Analysis Across the Globe: How Feasible Is It Really?

    Dec 1, 2025, 00:00

  • EE358 Economic Burden of COPD in Algeria: A Retrospective Analysis of Healthcare Resource Utilization and Costs

    Dec 1, 2025, 00:00

  • EPH198 Public Health Impact of 25 Years of Pneumococcal Conjugate Vaccination in Children 5 Years Old: A Modeling Analysis

    Dec 1, 2025, 00:00

  • RWD3 A Proof of Concept Study to Build a Japanese-Based Electronic Medical Record Data Model Suited for Real-World Research

    Dec 1, 2025, 00:00

  • HPR104 From Policy to Practi Are Larger Member States Leading the Way for Joint Clinical Assessments?

    Dec 1, 2025, 00:00

  • SA100 Use of Innovative Methods in Long-Term Follow-up Observational Studies: An AI-Enabled Targeted Literature Review

    Dec 1, 2025, 00:00

  • MT44 Unraveling the Challenges of Multiplex Cell Culture Technology Using the HTA Core Model

    Dec 1, 2025, 00:00

  • HTA45 Assessing the Cost-Effectiveness of Lecanemab for Early Alzheimer's Disease Treatment: A Swiss Perspective

    Dec 1, 2025, 00:00
  • 1 (current)
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • »